Literature DB >> 8942507

The importance of urinary protein excretion during conservative management of severe preeclampsia.

E Schiff1, S A Friedman, L Kao, B M Sibai.   

Abstract

OBJECTIVES: We determined the natural course of urinary protein excretion during conservative management of severe preeclampsia and investigated whether changes in urinary protein excretion can predict maternal or perinatal outcome. STUDY
DESIGN: We reviewed the medical charts of 66 women with severe preeclampsia which was managed conservatively before 32 weeks of gestation and who had at least two 24-hour urinary protein determinations 4 or more days apart after admission.
RESULTS: Fifty-nine (89%) of 66 women had an increase in proteinuria during conservative management of severe preeclampsia. The median increase in protein excretion after admission was 660 mg/24 hours (range-4580 to 18,960 mg/24 hours). Patients were divided into two groups. The first group (n = 24) had an increase in 24-hour urinary protein excretion of > or = 2 gm; the second group (n = 42) had a 24-hour urinary protein excretion that decreased (n = 7) or increased by < 2 gm (n = 35). There were no cases of eclampsia or stillbirth in either group. The rate of HELLP (hemolysis, elevated liver enzyme levels, low platelet counts) syndrome, abruptio placentae, cesarean delivery because of fetal distress, 5-minute Apgar scores < or = 6, and the admission-to-delivery intervals were all similar in the two groups.
CONCLUSIONS: Proteinuria increases in most women with severe preeclampsia managed conservatively. No differences in maternal or fetal outcomes were found between pregnancies with marked increases in proteinuria and those with modest or no increases.

Entities:  

Mesh:

Year:  1996        PMID: 8942507     DOI: 10.1016/s0002-9378(96)70047-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Assessment of proteinuria in pregnancy.

Authors:  Lucy C Chappell; Andrew H Shennan
Journal:  BMJ       Date:  2008-04-10

2.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

3.  Pregnancies complicated by preeclampsia and non-preeclampsia-related nephrotic range proteinuria.

Authors:  R A Brown; G J Kemp; S A Walkinshaw; Mlp Howse
Journal:  Obstet Med       Date:  2013-08-13

4.  Hypertension in pregnancy: new recommendations for management.

Authors:  R Shear; L Leduc; E Rey; J M Moutquin
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

Review 5.  Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review.

Authors:  Anne-Marie Côté; Mark A Brown; Elaine Lam; Peter von Dadelszen; Tabassum Firoz; Robert M Liston; Laura A Magee
Journal:  BMJ       Date:  2008-04-10

6.  Is massive proteinuria associated with maternal and fetal morbidities in preeclampsia?

Authors:  Mi Jung Kim; Young Nam Kim; Eun Jung Jung; Hye Ree Jang; Jung Mi Byun; Dae Hoon Jeong; Moon Su Sung; Kyung Bok Lee; Ki Tae Kim
Journal:  Obstet Gynecol Sci       Date:  2017-05-15

7.  The association between protein levels in 24-hour urine samples and maternal and neonatal outcomes of pregnant women with preeclampsia.

Authors:  Gülşah Aynaoğlu Yıldız; Emsal Pınar Topdağı Yılmaz
Journal:  J Turk Ger Gynecol Assoc       Date:  2022-09-05

8.  ASH position paper: hypertension in pregnancy.

Authors:  Marshall D Lindheimer; Sandra J Taler; F Gary Cunningham
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-04       Impact factor: 3.738

Review 9.  Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review.

Authors:  Shakila Thangaratinam; Arri Coomarasamy; Fidelma O'Mahony; Steve Sharp; Javier Zamora; Khalid S Khan; Khaled M K Ismail
Journal:  BMC Med       Date:  2009-03-24       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.